Abstract: An array substrate, an opposite substrate and a display panel are provided. The array substrate comprises: a display region and a periphery region surrounding the display region, wherein the display region comprises a plurality of pixel regions, and each of the pixel regions comprises a reflective region and a transmissive region; the reflective region comprises a driving signal outputting layer, a segment gap layer, a passivation layer and a reflective layer, the reflective layer is coupled to the driving signal outputting layer to enable both the reflective layer and the driving signal outputting layer to function as a reflective region driving electrode; the transmissive region comprises a first electrode layer, the first electrode layer is coupled to the driving signal outputting layer, the passivation layer extends to the transmissive region, and the passivation layer is arranged between the first electrode layer and a first base of the display substrate.

Abstract: Composite particles of the present invention include alumina particles and an inorganic coating disposed on a surface of the alumina particles, the alumina particles containing molybdenum (Mo), the inorganic coating including a composite metal oxide.

Abstract: The embodiments of the disclosure are applicable to the technical field of blockchain and provide a consensus trusted cluster changing method, a computer device and a computer-readable storage medium. The method is applicable to a blockchain and includes: determining a current epoch of a newly added validator node of the consensus trusted cluster in the blockchain and a target epoch of the consensus trusted cluster; requesting target status information and proof of target cluster change from a target validator node in the target epoch; verifying the target status information according to the proof of target cluster change; and updating, in case where the target status information has been verified, status information of the newly added validator node according to the target status information to complete change of the consensus trusted cluster. Through the above method, a trusted synchronization target status may be determined.

Abstract: The present disclosure provides methods and compositions useful for diagnosing and treating activated alternative pathway of complement in a human subject with a SARS-CoV-2 infection. Also provided are methods of treating an infection by a betacoronavirus, e.g., SARS-CoV, MERS-CoV, or SARS-CoV-2, in a human subject. The methods of treatment include administering to the human subject a therapeutically effective amount of at least one complement factor D inhibitor. Also provided herein are compounds for treating an infection by a betacoronavirus and their use in the manufacture in a medicament for treating an infection by a betacoronavirus.

Abstract: A MINI LED driving power supply and a MINI LED television, the MINI LED driving power supply includes a power supply board connecting with a mainboard and a MINI LED screen, the power supply board includes a first conversion module and a second conversion module; the first conversion module outputs power supply voltage to power the mainboard after the first conversion module is turned on, outputs first voltage and second voltage to power the mainboard according to a power-on/off signal output by the mainboard, and outputs first power supply and high-voltage direct current to the second conversion module; the second conversion module converts high-voltage direct current into third voltage and outputs the third voltage to the MINI LED screen according to enable signal output by the mainboard and the first power supply, to light up MINI LED screen.

Abstract: The present invention relates generally to the field of disorders of complement activation. More specifically, the present invention provides methods and compositions useful for identifying patients having a complement-mediated disease that could benefit from treatment with complement inhibitors. As described herein, the present invention utilizes patient sera and flow cytometry in the companion diagnostic assay. More specifically, the present invention comprises evaluating complement activity via cell surface deposition of C5b-9 and, in further embodiments, complement-dependent cell killing (the modified Ham assay) using patient sera.